Pfizer acquires Trillium Therapeutics for $2.22bn
Pfizer has completed the acquisition of all outstanding shares of clinical-stage immuno-oncology firm Trillium Therapeutics in a deal worth about $2.22bn, or $18.50 per share, in cash. The
Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation by the European regulatory authorities for Novo Nordisk’s anti-obesity medication Wegovy.